- Sai Life Sciences has begun construction of a new CMC Process R&D Centre at its integrated R&D campus in Hyderabad, India.
- The 100,000 sq. ft. facility is expected to double Process R&D capacity and add new capabilities in peptides, oligos, formulations, and early clinical supplies by September 2026.
Sai Life Sciences Limited, a Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the groundbreaking of its new CMC Process R&D Centre at its integrated R&D campus in Hyderabad. Scheduled for completion by September 2026, the facility will double the company’s Process R&D capacity while introducing new scientific capabilities.
The 100,000 sq. ft. (9300 sq.m.) facility will feature 140 process chemistry fume hoods, a 25,000 sq. ft. analytical laboratory, and dedicated labs for peptide and oligo intermediates and linkers development. It will also include NCE formulation development, early-phase clinical supply capabilities, and containment down to OEL 4 (1 µg/m³).
Designed as a green building, the new centre will support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models. This approach will enable greater flexibility for collaborations with global innovators across early and late-stage CMC development programmes.
“As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programs faster and more efficiently through the development continuum.”
Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences
The investment forms part of the company’s ongoing capital expenditure plans, driven by growing demand for larger clinical-scale programmes and scalable capacity across contract manufacturing and development. Sai Life Sciences stated that the new centre reinforces its focus on scale, sustainability, and partnership-driven innovation.
